Howard L. Kaufman, MD, FACS, associate director for clinical science and chief surgical officer at Rutgers Cancer Institute of New Jersey, will serve as editor-in-chief of The Journal of Targeted Therapies in Cancer and Targeted Therapies in Oncology.
Howard L. Kaufman, MD, FACS
Targeted Healthcare Communications, the nation’s leading digital and print media enterprise, focused on targeted cancer therapies, today announced that Howard L. Kaufman, MD, FACS, associate director for clinical science and chief surgical officer at Rutgers Cancer Institute of New Jersey, will serve as editor-in-chief of The Journal of Targeted Therapies in Cancer™ (JTT) and Targeted Therapies in Oncology™ (TTO).
In this role, Dr. Kaufman will work with the editorial staff of each journal to map out content for every issue, including the authoring of a column for each issue. He will also provide topics and recommend physicians for original manuscript solicitation, review final layouts before going to print, and recommend physicians for the peer-review process. Additionally, Dr. Kaufman will work with the editorial teams to continually assess the journals’ editorial boards.
“Dr. Kaufman was invited to take on the role of editor-in-chief for both JTT and TTO in recognition of his considerable achievements in targeted therapies through his work at Rutgers Cancer Institute of New Jersey and throughout his impressive career as a leading surgical oncologist and researcher,” said Mike Hennessy Jr., president of Targeted Healthcare Communications. “We’re certain his leadership, expertise and vision for the future of targeted therapies will enable him to take the editorial content of JTT and TTO to a new level of excellence for our readers.”
A renowned expert in melanoma, Merkel cell cancer and tumor immunotherapy, and the president of the Society for Immunotherapy of Cancer, Dr. Kaufman’s role at Rutgers Cancer Institute of New Jersey allows him to work with an established team of dedicated doctors and scientists to find new treatments for patients with melanoma and related skin cancers. Over the course of his extensive career in cancer treatment, Dr. Kaufman established the Columbia University Melanoma Center and a National Institutes of Health-funded laboratory in tumor immunology in New York, as well as the Rush Melanoma Center in Chicago. He has also served on numerous boards and has published more than 200 scientific papers, books, book chapters, and abstracts, including The Melanoma Book, a resource for patients and family members dealing with the diagnosis of melanoma.
“The Journal of Targeted Therapies in Cancer and Targeted Therapies in Oncology are two of the nation’s leading journals on targeted therapies, which align thoroughly with my cancer background,” said Dr. Kaufman. “I’m looking forward to working with the editorial teams to create engaging content to educate and enlighten our readers on targeted therapies and related topics, issues, advancements and trends.”
About Targeted Healthcare Communications
As cancer treatment has evolved dramatically over the past 10 years, with advances born of significant progress in the understanding of tumor development, genetics, and pathology, the discovery of new pathways has transformed cancer treatment from chemotherapy regimens to advanced, and sometimes complicated targeted treatment options. Targeted Healthcare Communications leverages the growing interest in cancer products in precision medicine and is the first publisher with a peer-reviewed journal focusing on these new products. Through digital and print media platforms, the organization offers a dedicated website, two journals, and a number of multichannel programs focused on precision medicine in oncology. Targeted Healthcare Communications is part of Michael J. Hennessy Associates, Inc., a full-service healthcare communications company offering education, research, medical media, and the acclaimed Targeted Oncology digital platform of resources on next-generation therapeutics and their molecular targets for practicing oncologists.